With Hinge Health filing to go public, are we... back?
When Hinge Health filed to go public on Monday afternoon, I’ll admit I was caught off guard. In part, because the stock market had its worst day of the year. But ...
View ArticleMeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene...
A small-cap biotech developing gene therapies is spinning out its Parkinson’s disease program into a new company in partnership with a secretive AI startup co-founded by former Google CEO Eric Schmidt....
View ArticlePfizer terminates an early-stage STING agonist trial
Pfizer's pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a spokesperson confirmed to Endpoints News. The company ended a Phase 1 trial of...
View ArticleMoonLake's CEO on its looming mid-year pivotal readout in skin disease
MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry's biggest stock-moving clinical readouts around the middle of this year for a pair of Phase 3 trials in a painful...
View ArticleLilly-partnered Fauna Bio plans $40M Series A to get into heart failure
MIAMI — Fauna Bio, a biotech that mines data on disease resistance from squirrels and other animals to create new drugs, is looking at raising a Series A to get its first program into clinical trials ...
View ArticleMerck diversity leader to retire this summer; Geron seeks commercial chops...
→ Celeste Warren said in a LinkedIn post that she is retiring from Merck on July 7. Warren joined Merck in 1997 and has been VP of the company’s Global Diversity ...
View ArticleSutro slashes workforce in half, changes CEO and closes factory
Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away from its lead candidate. The major reshuffle is intended to save cash, which...
View ArticleAltimmune to put its incretin into addiction trials; Tarsus aims to raise $125M
Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction: Following the path set by Novo Nordisk last week, Altimmune said...
View ArticleRFK Jr. convened roundtable around ways to reduce stem cell regulation
HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to discuss how to lower regulatory barriers for stem cell treatments, three people...
View ArticleRecipharm hits record revenue, eyes GLP-1 deals for growth
Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO. The CDMO reported record-high revenues on Friday, and the company expects it will be able to tap into the booming GLP ...
View ArticleUK’s drugmaker rebate plan draws scrutiny from industry
The UK government is planning to double the proportion of money drugmakers have to pay back on medicine sales to the National Health Service in a move that’s drawn backlash from industry. In the UK ...
View ArticleBoston Pharma mulls IPO amid MASH momentum
The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And another late-stage startup is gaining traction. Boston Pharmaceuticals,...
View ArticleFederal Circuit ruling keeps Amgen's Eylea biosimilar on the market
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement case involving the New York biotech's blockbuster eye drug Eylea and Amgen's...
View ArticleDr. Oz says he would defend Medicare drug price negotiations
Mehmet Oz has committed to defending Medicare drug price negotiations in court if he is confirmed to lead CMS. The nominee sailed through a roughly three-hour confirmation hearing on Friday, despite...
View ArticleUpdates on health agency nominees; New data from Pfizer, Beam; MASH startup...
Welcome back to Endpoints Weekly. Our reporters tracked a flurry of deals and data readouts this week, plus updates on the Trump administration’s health agency picks. Let’s dive in. The Trump...
View ArticleEli Lilly-backed Maxion Therapeutics raises $72M Series A to advance its...
Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates. The proceeds should give Maxion enough...
View ArticleLatigo collects $150M to get non-opioid data to compete with Vertex in acute...
Latigo Biotherapeutics thinks it can one-up Vertex Pharmaceuticals' recently approved Journavx, which ignited the non-opioid landscape for treating pain. The Los Angeles-area biotech is testing a...
View ArticleAstraZeneca to buy cell therapy startup EsoBiotec for $425M upfront
AstraZeneca said Monday that it has agreed to acquire a cell therapy biotech founded just four years ago for an upfront payment of $425 million. The UK pharma has also promised up to $575 million ...
View ArticleAvidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drug
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed a Phase 1/2 study, and the biotech...
View ArticleHC Bioscience, a tRNA biotech backed by ARCH and Takeda, shuts down
A Boston biotech trying to bring transfer RNA (tRNA) biology to the drug development field has shuttered operations, Endpoints News has learned. The startup, called HC Bioscience, broke onto the scene...
View Article